Skip to Content

Rule

Animal Drugs, Feeds, and Related Products; Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Cuprimyxin; Diethylcarbamazine; Levamisole; Nitrofurazone; Phenylbutazone; Pyrantel; Tylosin; Tylosin and Sulfamethazine

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendment.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations by removing those portions that reflect approval of 13 new animal drug applications (NADAs). In a notice published elsewhere in this issue of the Federal Register, FDA is withdrawing approval of these NADAs.

DATES:

This rule is effective April 11, 2011.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

John Bartkowiak, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9079, e-mail: john.bartkowiak@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

The sponsors of the 13 approved NADAs listed in table 1 have requested that FDA withdraw approval because the products are no longer manufactured or marketed.

Start Printed Page 17777

Table 1—Voluntary Requests for Withdrawal of Approval of 13 NADAs

SponsorNADA No. product (established name of drug)21 CFR section affected (sponsor's drug labeler code)
Roche Vitamins, Inc., 45 Waterview Blvd., Parsippany, NJ 07054-1298NADA 093-029, UNITOP Cream (cuprimyxin)524.520 (063238).
Quali-Tech Products, Inc., 318 Lake Hazeltine Dr., Chaska, MN 55318NADA 097-981, TYLAN 40 Sulfa-G Premix (tylosin phosphate/sulfamethazine)558.630 (016968).
Abraxis Pharmaceutical Products, Division of Abraxis Bioscience, 6133 River Rd., suite 500, Rosemont, IL 60018NADA 100-840, Chorionic Gonadotropin for Injection (chorionic gonadotropin)522.1081 (063323).
Furst-McNess Co., Freeport, IL 61032NADA 100-991, McNess Custom Premix L200 (tylosin phosphate)558.625 (010439).
Fort Dodge Animal Health, Division of Wyeth Holdings, a wholly owned subsidiary of Pfizer, Inc., 235 East 42d St., New York, NY 10017NADA 101-079 TRAMISOL-10% Pig Wormer (levamisole)Not codified (000856).
Waterloo Mills Co., 2050 Mitchell Ave., Waterloo, IA 50704NADA 101-905, Mill Co-Medicator TY-10 (tylosin phosphate)558.625 (017139).
Waterloo Mills Co., 2050 Mitchell Ave., Waterloo, IA 50704NADA 101-906, Mill Co-Medicator TS-40 Premix (tylosin phosphate/sulfamethazine)558.630 (017139).
Pegasus Laboratories, Inc., 8809 Ely Rd., Pensacola, FL 32514NADA 102-824,Phenylbutazone Tablets (phenylbutazone)520.1720a (055246).
Wendt Laboratories, Inc., 100 Nancy Dr., Belle Plaine, MN 56011NADA 108-487, DEC Tabs (diethylcarbamazine citrate)520.622a (015579).
Wendt Laboratories, Inc., 100 Nancy Dr., Belle Plaine, MN 56011NADA 108-863, DEC Chewable Tabs (diethylcarbamazine citrate)520.622c (015579).
Furst-McNess Co., Freeport, IL 61032NADA 140-820, TYLAN 40 Sulfa-G Premix (tylosin phosphate/sulfamethazine)558.630 (010439).
Furst-McNess Co., Freeport, IL 61032NADA 140-825, BANMINTH Intermediate Premix (pyrantel tartrate)558.485 (010439).
Hess & Clark, Inc., 944 Nandino Blvd., Lexington, KY 40511NADA 140-910, NFZ Wound Powder (nitrofurazone)524.1580c (050749).

In a notice published elsewhere in this issue of the Federal Register, FDA gave notice that approval of NADAs 93-029, 97-981, 100-840, 100-991, 101-079, 101-905, 101-906, 102-824, 108-487, 108-863, 140-820, 140-825, and 140-910, and all supplements and amendments thereto, is withdrawn, effective April 11, 2011. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these withdrawals of approval and a current format.

Following these changes of sponsorship, Abraxis Pharmaceutical Products, Furst-McNess Co., Roche Vitamins, Inc., Waterloo Mills Co., and Wendt Laboratories, Inc., are no longer the sponsors of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for these firms.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

, 522, and 524

End List of Subjects

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, and 558 are amended as follows:

Start Part

PART 510—NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority
[Amended]
Start Amendment Part

2. In § 510.600, in the table in paragraph (c)(1), remove the entries for “Abraxis Pharmaceutical Products”, “Furst-McNess Co.”, “Roche Vitamins, Inc.”, “Waterloo Mills Co.”, and “Wendt Laboratories, Inc.”; and in the table in paragraph (c)(2), remove the entries for “010439”, “015579”, “017139”, “063238”, and “063323”.

End Amendment Part Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

3. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority Start Amendment Part

4. In § 520.622a, remove and reserve paragraph (a)(1); in paragraph (a)(5), remove “000081' and in its place add “No. 000061”; and revise paragraph (b)(2) to read as follows:

End Amendment Part
Diethylcarbamazine citrate tablets.
* * * * *

(b) * * *

(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Start Amendment Part

5. In § 520.622c, remove and reserve paragraph (b)(1); remove reserved paragraph (b)(7); and revise paragraph (c)(3) to read as follows:

End Amendment Part
Diethylcarbamazine citrate chewable tablets.
* * * * *

(c) * * *

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[Amended]
Start Amendment Part

6. In § 520.1720a, remove and reserve paragraph (b)(4).

End Amendment Part Start Part Start Printed Page 17778

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

7. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

8. In paragraph (b)(2) of § 522.1081, remove “Nos. 058639 and 063323” and in its place add “No. 058639”.

End Amendment Part Start Part

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

9. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Removed]
Start Amendment Part

10. Remove § 524.520.

End Amendment Part
[Amended]
Start Amendment Part

11. In paragraph (b) of § 524.1580c, remove “Nos. 000010, 000069, and 050749” and in its place add “Nos. 000010 and 000069”.

End Amendment Part Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part Start Amendment Part

12. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority
[Amended]
Start Amendment Part

13. In § 558.485, in paragraph (b)(3), remove “010439”.

End Amendment Part
[Amended]
Start Amendment Part

14. In § 558.625, remove and reserve paragraphs (b)(42) and (b)(45).

End Amendment Part
[Amended]
Start Amendment Part

15. In § 558.630, remove and reserve paragraph (b)(4); and in paragraph (b)(5), remove “010439,” and “016968,”.

End Amendment Part Start Signature

Dated: March 25, 2011.

Leslie Kux,

Acting Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2011-7560 Filed 3-30-11; 8:45 am]

BILLING CODE 4160-01-P